Loading patent…
AssigneeInstitute National De La Sante ET De Las Recherche Medicale (INSERM)
InventorsThierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
Estimating the term…
The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising:
A method, for treating and/or preventing a neurodegenerative, disorder comprising the administration of an effective amount comprising the administration of an effective amount of a compound selected in the group comprising:
A method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder, which comprises the step of analyzing a biological sample from said subject for:
Dependencies are inferred from the claim text.